1 / 13

Power

THE FUTURE OF FIGHTING CANCER How to increase cancer cure rate by 30% by 2030. Power. SDS Optic Inc. Lublin, Poland. Presentation Template. There are more than 100 types of cancers – most defined by tumor biology & cancer biomarkers. Almost 9 million people die each year from cancer.

davidgray
Download Presentation

Power

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. THE FUTURE OF FIGHTING CANCER How to increasecancercurerate by 30% by 2030 Power SDS Optic Inc. Lublin, Poland Presentation Template

  2. There are more than 100 types of cancers – most defined by tumor biology & cancer biomarkers Almost 9 millionpeople die each year from cancer 70% - the increase in new cases of cancer expected over the next 2 decades * Source: World Health Organization http://www.who.int/mediacentre/factsheets/fs297/en/

  3. FACTS & CHALLANGES The Future of cancer treatment is here … Targeted-Immune-Gene-Cell/CAR-T Therapies 2 milion newcases of BreastCancer in 2018, 0.5 milion deaths. Major reason – LATE or FALSE diagnosis and no treatment monitoring technologies Real-Time in vivo & no false targeted tumor biology diagnostics is KEY Average age of Pathologists in Europe has just exceeded 60 years, with very few young annual additions

  4. WHERE TARGET THERAPIES MEET TARGET DIAGNOSTICS Invented in the U.S. Designed & Developed in Poland €9M raised to date

  5. Disruptive 6-micron opto-biological Platform Technology Merging fiber optics, biotech and engineering Single-cell resolution Microprobe Challenging the Paradigm HER2 tumor biomarker in breast cancers as first in-human clinical application

  6. KeyBenefits in cancerdiagnosis • In-vivo examination and real timeresults No tissuebiopsy. Results in 15-20 mins • High Sensitivity No tumor infraction. Enough to getclose to the tumor with USG guidance • Objectiveresults Numericalresults. No more FALSE POSITIVE or FALSE NEGATIVE results • Patientswellbeing No waitingtime. Immediate personalizedtargetedtreatmentintroduction • Numerousscale-uppossibilities Most cancerbiomarkers, real-timetreatment monitoring

  7. HER2+ CancersClinicalChallenges – where we canhelp? • Visual examination • False -/+ results • Has DRUG been delivered to the tumor area ? • Inject less or more? WHO will benefit from specific targeted treatment ? Increase cancer complete remissions by 30% by 2030

  8. Disruptive platform technology with widescale-upopportunites

  9. How we gethere

  10. OurAssets

  11. WhoTrustedUs

  12. Thankyou SDS Optic Inc. Konstantynow 1F 20-708 Lublin, POLAND www.sdsoptic.com www.inprobe.com Follow us:

More Related